Freund N, Wang H, Scharf L, Nogueira L, Horwitz J, Bar-On Y
Sci Transl Med. 2017; 9(373).
PMID: 28100831
PMC: 5467220.
DOI: 10.1126/scitranslmed.aal2144.
Bradley T, Fera D, Bhiman J, Eslamizar L, Lu X, Anasti K
Cell Rep. 2016; 14(1):43-54.
PMID: 26725118
PMC: 4706810.
DOI: 10.1016/j.celrep.2015.12.017.
Sargsyan O
PLoS One. 2014; 9(2):e87655.
PMID: 24516557
PMC: 3917834.
DOI: 10.1371/journal.pone.0087655.
Naif H
Infect Dis Rep. 2014; 5(Suppl 1):e6.
PMID: 24470970
PMC: 3892619.
DOI: 10.4081/idr.2013.s1.e6.
McLinden R, Paris R, Polonis V, Close N, Su Z, Shikuma C
AIDS. 2012; 26(11):1452.
PMID: 22767347
PMC: 3505760.
DOI: 10.1097/QAD.0b013e3283550b8e.
Analytical framework for identifying and differentiating recent hitchhiking and severe bottleneck effects from multi-locus DNA sequence data.
Sargsyan O
PLoS One. 2012; 7(5):e37588.
PMID: 22662176
PMC: 3360760.
DOI: 10.1371/journal.pone.0037588.
Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles.
Zhang H, Huang Y, Fayad R, Spear G, Qiao L
J Virol. 2004; 78(15):8342-8.
PMID: 15254206
PMC: 446118.
DOI: 10.1128/JVI.78.15.8342-8348.2004.
Rapid evolution of the neutralizing antibody response to HIV type 1 infection.
Richman D, Wrin T, Little S, Petropoulos C
Proc Natl Acad Sci U S A. 2003; 100(7):4144-9.
PMID: 12644702
PMC: 153062.
DOI: 10.1073/pnas.0630530100.
Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection.
Montefiori D, HILL T, Vo H, Walker B, Rosenberg E
J Virol. 2001; 75(21):10200-7.
PMID: 11581388
PMC: 114594.
DOI: 10.1128/JVI.75.21.10200-10207.2001.
Evidence for similar recognition of the conserved neutralization epitopes of human immunodeficiency virus type 1 envelope gp120 in humans and macaques.
Malenbaum S, Yang D, Cheng-Mayer C
J Virol. 2001; 75(19):9287-96.
PMID: 11533191
PMC: 114496.
DOI: 10.1128/JVI.75.19.9287-9296.2001.
Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12.
Zwick M, Bonnycastle L, Menendez A, Irving M, Barbas 3rd C, Parren P
J Virol. 2001; 75(14):6692-9.
PMID: 11413337
PMC: 114393.
DOI: 10.1128/JVI.75.14.6692-6699.2001.
Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals.
Moog C, Fleury H, Pellegrin I, KIRN A, Aubertin A
J Virol. 1997; 71(5):3734-41.
PMID: 9094648
PMC: 191523.
DOI: 10.1128/JVI.71.5.3734-3741.1997.
Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization.
Weber J, Fenyo E, Beddows S, Kaleebu P, Bjorndal A
J Virol. 1996; 70(11):7827-32.
PMID: 8892904
PMC: 190853.
DOI: 10.1128/JVI.70.11.7827-7832.1996.
Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.
Koup R, Safrit J, Cao Y, Andrews C, McLeod G, Borkowsky W
J Virol. 1994; 68(7):4650-5.
PMID: 8207839
PMC: 236393.
DOI: 10.1128/JVI.68.7.4650-4655.1994.
Immunopathogenic events in acute infection of rhesus monkeys with simian immunodeficiency virus of macaques.
Reimann K, Tenner-Racz K, Racz P, Montefiori D, Yasutomi Y, Lin W
J Virol. 1994; 68(4):2362-70.
PMID: 8139022
PMC: 236713.
DOI: 10.1128/JVI.68.4.2362-2370.1994.
Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection.
Borrow P, Lewicki H, Hahn B, Shaw G, Oldstone M
J Virol. 1994; 68(9):6103-10.
PMID: 8057491
PMC: 237022.
DOI: 10.1128/JVI.68.9.6103-6110.1994.
Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1.
Moore J, Cao Y, Ho D, Koup R
J Virol. 1994; 68(8):5142-55.
PMID: 8035514
PMC: 236458.
DOI: 10.1128/JVI.68.8.5142-5155.1994.
Interlaboratory variability of CD8 subset measurements by flow cytometry and its applications to multicenter clinical trials. NAID/NICHD Women and Infants Transmission Study Group.
Landay A, Brambilla D, Pitt J, Hillyer G, Golenbock D, Moye J
Clin Diagn Lab Immunol. 1995; 2(4):462-8.
PMID: 7583925
PMC: 170180.
DOI: 10.1128/cdli.2.4.462-468.1995.